A United Nations agency has urged the pharmaceutical company Gilead Sciences to lower the price of the long acting antiviral treatment lenacapavir following the US Food and Drug Administration (FDA)’s ...

The US FDA has approved lenacapavir, a biannual injection by Gilead, to prevent HIV, potentially revolutionizing the fight against the epidemic.

The United States Food and Drug Administration (FDA) has approved long-acting injectable lenacapavir for HIV prevention. The ...

The US Food and Drug Administration (FDA) has approved use of the vaccine Yeztugo, manufactured by Gilead Sciences, is an anti-HIV drug.

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...

General, Winnie Byanyima, has called for a drastic and transparent reduction in the cost of lenacapavir, a twice-yearly ...

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move ...

Lenacapavir, the world's first twice-yearly HIV prevention shot, gets US FDA nod-offering a discreet, long-acting solution ...

Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection: Foster City, California Friday, June 20, 2025, 1 ...

The Food and Drug Administration has approved a highly effective new HIV prevention medication, known as Yeztugo. In clinical ...